in face of the backlog of patent examinations in Brazil, considering its hushed enrollment to the Trade-Related Aspects of Intellectual Property Rights Agreement (TRIPS), this work evidences the impact pharmaceutical patents to expire until 2022 in the pharmaceutical industry in Brazil, highlighting the positive and negative effects of the extended patent-term in Brazil guaranteed by the article 40 of LPI 9,279/96 to late-granted patent, on the competitiveness of Brazilian industry. In 2021, this regulation was modified, leading to another serious impact that had immediate influence on the industrial behavior. These aspects were evaluated under a technical point of view.
- Society
Editorial Board
The ESMED Editorial Board is comprised of experts from around the world.
Meet the community
See what our members have been working on.
Membership
Join ESMED for access to member-only content, congress discounts, and more.
